Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO1997017064) STABLE FREEZE-DRIED PHARMACEUTICAL FORMULATION
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/1997/017064 International Application No.: PCT/FR1996/001706
Publication Date: 15.05.1997 International Filing Date: 30.10.1996
Chapter 2 Demand Filed: 25.04.1997
IPC:
A61K 9/19 (2006.01) ,A61K 47/18 (2006.01) ,A61K 47/26 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9
Medicinal preparations characterised by special physical form
14
Particulate form, e.g. powders
19
lyophilised
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47
Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
06
Organic compounds
16
containing nitrogen
18
Amines; Quaternary ammonium compounds
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47
Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
06
Organic compounds
26
Carbohydrates
Applicants:
SANOFI [FR/FR]; 32-34, rue Marboeuf F-75008 Paris, FR (AllExceptUS)
BOULOUMIE, Colette [FR/FR]; FR (UsOnly)
BREUL, Thierry [FR/FR]; FR (UsOnly)
COLLIERE, Laurence [FR/FR]; FR (UsOnly)
FAURE, Philippe [FR/FR]; FR (UsOnly)
Inventors:
BOULOUMIE, Colette; FR
BREUL, Thierry; FR
COLLIERE, Laurence; FR
FAURE, Philippe; FR
Agent:
LE GUEN, Gérard; Cabinet Lavoix 2, place d'Estienne-d'Orves F-75441 Paris Cédex 09, FR
Priority Data:
95/1302203.11.1995FR
Title (EN) STABLE FREEZE-DRIED PHARMACEUTICAL FORMULATION
(FR) FORMULATION PHARMACEUTIQUE LYOPHILISEE STABLE
Abstract:
(EN) A pharmaceutically acceptable freeze-dried formulation consisting of an amorphous phase and a crystalline phase and including at least one non-protein active principle. The formulation is characterised in that it contains mannitol and alanine in a ratio R of 0.1-1, where R is the weight of mannitol over the weight of alanine.
(FR) L'invention a pour objet une formulation lyophilisée constituée d'une phase amorphe et d'une phase cristalline, pharmaceutiquement acceptable comprenant au moins un principe actif non protéique, caractérisée en ce qu'elle contient du mannitol et de l'alanine dans un rapport R compris entre 0,1 et 1, R représentant la masse de mannitol sur la masse d'alanine.
Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN
African Regional Intellectual Property Organization (ARIPO) (KE, LS, MW, SD, SZ, UG)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG)
Publication Language: French (FR)
Filing Language: French (FR)
Also published as:
CZPV1998-1231IS4729NO19981967SK52598TR1998/00782SG53586
VN0854IL124214ES2180805EP0858325RU02163801US6284277
EE9800123JPH11507945 CN1203527CA2234140DE000069622735PT858325
KR1019990067325NZ321616AU1996074990FR2740686DK0858325MYPI 96004556